Iskalni niz je ali predolg ali pa vsebuje preveč besed.
Prevodi: en > sl
101–112/112
TC
101 Prevajalska redakcija
RS
EMEA
Patients taking Pelzont (2000 mg/ 40 mg) with or without a statin, versus placebo, had significantly decreased LDL-C (-18.9 % vs. -0.5 %), TG (-21.7 % vs. 3.6 %), LDL-C: HDL-C (-28.9 % vs. 2.3 %), non-HDL-C (-19.0 % vs. 0.8 %), apo B (-16.4 % vs. 2.5 %), TC (-9.2 % vs. -0.6 %), Lp(a) (-17.6 % vs. 1.1 %), and TC: HDL-C (-21.2 % vs. 1.9 %) and also had significantly increased HDL-C (18.8 % vs. -1.2 %), and apo A-I (11.2 % vs. 4.3 %) as measured by percent change from baseline.
Bolnikom, ki so jemali zdravilo Pelzont 2000 mg/ 40 mg s statinom ali brez njega, so se v primerjavi s prejemniki placeba bistveno znižali hLDL (- 18, 9 % v prim. z - 0, 5 %), trigliceridi (- 21, 7 % v prim. s 3, 6 %), razmerje hLDL: hHDL (- 28, 9 % v prim. z 2, 3 %), ne- HDL- holesterol (- 19, 0 % v prim. z 0, 8 %), apo B (- 16, 4 % v prim. z 2, 5 %), Ch (- 9, 2 % v prim. z - 0, 6 %), Lp(a) (- 17, 6 % v prim. z 1, 1 %), in razmerje Ch: hHDL (- 21, 2 % v prim. z 1, 9 %), bistveno pa sta se jim zvišala hHDL (18, 8 % v prim. z 1, 2 %) in apo A- I (11, 2 % v prim. s 4, 3 %), merjeno v odstotkih spremembe od izhodišča.
102 Prevajalska redakcija
RS
EMEA
Patients taking Trevaclyn (2000 mg/ 40 mg) with or without a statin, versus placebo, had significantly decreased LDL-C (-18.9 % vs. -0.5 %), TG (-21.7 % vs. 3.6 %), LDL-C: HDL-C (-28.9 % vs. 2.3 %), non-HDL-C (-19.0 % vs. 0.8 %), apo B (-16.4 % vs. 2.5 %), TC (-9.2 % vs. -0.6 %), Lp(a) (-17.6 % vs. 1.1 %), and TC: HDL-C (-21.2 % vs. 1.9 %) and also had significantly increased HDL-C (18.8 % vs. -1.2 %), and apo A-I (11.2 % vs. 4.3 %) as measured by percent change from baseline.
Bolnikom, ki so jemali zdravilo Trevaclyn 2000 mg/ 40 mg s statinom ali brez njega, so se v primerjavi s prejemniki placeba bistveno znižali hLDL (- 18, 9 % v prim. z - 0, 5 %), trigliceridi (- 21, 7 % v prim. s 3, 6 %), razmerje hLDL: hHDL (- 28, 9 % v prim. z 2, 3 %), ne- HDL- holesterol (- 19, 0 % v prim. z 0, 8 %), apo B (- 16, 4 % v prim. z 2, 5 %), Ch (- 9, 2 % v prim. z - 0, 6 %), Lp(a) (- 17, 6 % v prim. z 1, 1 %), in razmerje Ch: hHDL (- 21, 2 % v prim. z 1, 9 %), bistveno pa sta se jim zvišala hHDL (18, 8 % v prim. z 1, 2 %) in apo A- I (11, 2 % v prim. s 4, 3 %), merjeno v odstotkih spremembe od izhodišča.
103 Prevajalska redakcija
RS
EMEA
Patients taking Tredaptive (2000 mg/ 40 mg) with or without a statin, versus placebo, had significantly decreased LDL-C (-18.9 % vs. -0.5 %), TG (-21.7 % vs. 3.6 %), LDL-C: HDL-C (-28.9 % vs. 2.3 %), non-HDL-C (-19.0 % vs. 0.8 %), apo B (-16.4 % vs. 2.5 %), TC (-9.2 % vs. -0.6 %), Lp(a) (-17.6 % vs. 1.1 %), and TC: HDL-C (-21.2 % vs. 1.9 %) and also had significantly increased HDL-C (18.8 % vs. -1.2 %), and apo A-I (11.2 % vs. 4.3 %) as measured by percent change from baseline.
Bolnikom, ki so jemali zdravilo Tredaptive 2000 mg/ 40 mg s statinom ali brez njega, so se v primerjavi s prejemniki placeba bistveno znižali hLDL (- 18, 9 % v prim. z - 0, 5 %), trigliceridi (- 21, 7 % v prim. s 3, 6 %), razmerje hLDL: hHDL (- 28, 9 % v prim. z 2, 3 %), ne- HDL- holesterol (- 19, 0 % v prim. z 0, 8 %), apo B (- 16, 4 % v prim. z 2, 5 %), Ch (- 9, 2 % v prim. z - 0, 6 %), Lp(a) (- 17, 6 % v prim. z 1, 1 %), in razmerje Ch: hHDL (- 21, 2 % v prim. z 1, 9 %), bistveno pa sta se jim zvišala hHDL (18, 8 % v prim. z 1, 2 %) in apo A- I (11, 2 % v prim. s 4, 3 %), merjeno v odstotkih spremembe od izhodišča.
104 Prevajalska redakcija
izobraževanje
CELEX: 31992L0069
The IC content of the test chemical suspension in the mineral medium at the beginning of the test must be less than 5 % of the TC, and the total CO2 evolution in the inoculum blank at the end of the test should not normally exceed 40 mg/l medium.
Vsebnost IC v suspenziji preskusne snovi v mineralnem mediju mora biti na začetku preskusa manj kot 5 % TC in skupni CO2, razvit v slepem vzorcu z inokulumom, na koncu preskusa ne sme preseči 40 mg/l medija.
105 Prevajalska redakcija
izobraževanje
CELEX: 31972L0199
THIS METHOD MAKES IT POSSIBLE TO DETERMINE THE LEVELS OF CHLORTETRACYCLINE (CTC), OXYTETRACYCLINE (OTC) AND TETRACYCLINE (TC) WHERE CONCENTRATIONS ARE GREATER THAN 1 G PER KG, PROVIDED THERE IS NO INTERFERENCE FROM OTHER SUBSTANCES CLOUDING THE EXTRACTS.
S to metodo je mogoče določiti ravni klortetraciklina (CTC), oksitetraciklina (OT) in tetraciklina (TC), kjer so koncentracije večje od 1 g na kg, če ekstrakti niso motni zaradi drugih snovi.
106 Prevajalska redakcija
izobraževanje
CELEX: 32002D0231
Assessment and verification: the applicant shall provide a calculation of the total use of VOCs during final shoe production, together with supporting data, test results and documentation as appropriate, with the calculation made using CEN TC 309 WI 065 - 4.7.
Ocenjevanje in preverjanje: vlagatelj predloži izračun skupne uporabe HOS med končno izdelavo čevljev, skupaj s spremljajočimi podatki, rezultati preskusov in dokumentacijo, kakor je primerno, z izračunom ob uporabi CEN TC 309 WI 065 - 4.7.
107 Prevajalska redakcija
RS
EMEA
Nicotinic acid inhibits release of free fatty acids (FFA) from adipose tissue, which may contribute to the reduced plasma LDL-C, TC, VLDL-C, apo B, TG, and Lp(a), as well as elevated HDL-C, and apo A-I, all of which are associated with lower cardiovascular risk.
Nikotinska kislina zavira sproščanje prostih maščobnih kislin (PMK) iz maščobnega tkiva. To morda pripomore k znižanju hLDL, Ch, hVLDL, apo B, TG, in Lp(a) v plazmi ter k zvišanju HDL in apo A- I; vse to zmanjšuje srčno- žilno tveganje.
108 Prevajalska redakcija
izobraževanje
CELEX: 32002D0272
Commercial blocks (according to the rough block definition in CEN/TC 246/N.237 prEN 12670 "Natural stones - Terminology") refers to the basis of utilisable stone consisting of rock from quarries suitable for further processing in order to obtain slabs or other architectural items.
Komercialni bloki (glede na opredelitev surovega bloka v CEN/TC 246/N.237 prEN 12670 "Naravni kamni" - Terminologija) se navezujejo na osnovo uporabnega kamna iz kamnoloma za nadaljnjo obdelavo, primernega, da se pridobi plošče ali druge arhitekturne enote.
109 Prevajalska redakcija
RS
EMEA
All patients had at least 3 of the pre-defined cardiovascular risk factors: male gender, age ≥ 55 years, smoking, diabetes, history of CHD in a first-degree relative, TC: HDL-C > 6, peripheral vascular disease, left ventricular hypertrophy, prior cerebrovascular event, specific ECG abnormality, proteinuria/ albuminuria.
Vsi bolniki so imeli vsaj 3 od naslednjih, vnaprej določenih dejavnikov kardiovaskularnega tveganja: moški spol, starost ≥ 55 let, kajenje, diabetes, anamnezo koronarne bolezni pri sorodniku v prvem kolenu, razmerje trigliceridi: HDL > 6, periferno žilno bolezen, hipertrofijo levega prekata, predhoden cerebrovaskularni dogodek, specifične nenormalnosti EKG ali proteinurijo/ albuminurijo.
110 Prevajalska redakcija
RS
EMEA
Nicotinic acid lowers the levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), very low density lipoprotein cholesterol (VLDL-C), apolipoprotein B (apo B, the major LDL protein), triglycerides (TG), and lipoprotein(a) (Lp(a), a modified LDL particle) and elevates the levels of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-I (apo A-I, the major protein component of HDL).
Nikotinska kislina znižuje koncentracijo LDL holesterola (hLDL), celotnega holesterola (Ch), VLDL holesterola (hVLDL), apolipoproteina B (apo B, glavne beljakovine LDL), trigliceridov (TG) in lipoproteina(a) (Lp(a), spremenjenega delca LDL) ter zvišuje koncentracijo HDL holesterola (hHDL) in apolipoproteina A- I (apo A- I, glavne beljakovinske sestavine HDL).
111 Prevajalska redakcija
RS
EMEA
In a multicentre, double-blind, 12-week factorial study, Trevaclyn 1000 mg/ 20 mg co-administered with simvastatin, when compared with simvastatin alone or Trevaclyn 1000 mg/ 20 mg alone, for 4 weeks, significantly lowered LDL-C (-44.2 %, -37.4 %, -8.2 % respectively), TG (-25.8 %, -15.7 %, -18.7 % respectively), TC (-27.9 %, -25.8 %, -4.9 % respectively) and significantly increased HDL-C (19.2 %, 4.2 %, 12.5 % respectively).
10 V multicentrični, dvojno slepi 12- tedenski faktorski študiji je 4- tedenska uporaba zdravila Trevaclyn 1000 mg/ 20 mg skupaj s simvastatinom v primerjavi s simvastatinom samim oz. z zdravilom Trevaclyn 1000 mg/ 20 mg samim bistveno znižala hLDL (- 44, 2 %, - 37, 4 % oz. - 8, 2 %), trigliceride (- 25, 8 %, - 15, 7 % oz. - 18, 7 %), Ch (- 27, 9 %, - 25, 8 % oz. - 4, 9 %) in bistveno zvišala hHDL (19, 2 %, 4, 2 % oz. 12, 5 %).
112 Prevajalska redakcija
RS
EMEA
In a multicentre, double-blind, 12-week factorial study, Tredaptive 1000 mg/ 20 mg co-administered with simvastatin, when compared with simvastatin alone or Tredaptive 1000 mg/ 20 mg alone, for 4 weeks, significantly lowered LDL-C (-44.2 %, -37.4 %, -8.2 % respectively), TG (-25.8 %, -15.7 %, -18.7 % respectively), TC (-27.9 %, -25.8 %, -4.9 % respectively) and significantly increased HDL-C (19.2 %, 4.2 %, 12.5 % respectively).
V multicentrični, dvojno slepi 12- tedenski faktorski študiji je 4- tedenska uporaba zdravila Tredaptive 1000 mg/ 20 mg skupaj s simvastatinom v primerjavi s simvastatinom samim oz. z zdravilom Tredaptive 1000 mg/ 20 mg samim bistveno znižala hLDL (- 44, 2 %, - 37, 4 % oz. - 8, 2 %), trigliceride (- 25, 8 %, - 15, 7 % oz. - 18, 7 %), Ch (- 27, 9 %, - 25, 8 % oz. - 4, 9 %) in bistveno zvišala hHDL (19, 2 %, 4, 2 % oz. 12, 5 %).
Prevodi: en > sl
101–112/112
TC